Baxter’s Gammagard Shows Alzheimer’s Benefit in Study

Updated on

Baxter International Inc.’s Gammagard, used to treat immune system disorders, halted the progression of Alzheimer’s disease for as long as three years in a trial of 16 patients, researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.